Marksans Pharma Ltd. announced that its Board of Directors, in a meeting held on July 11, 2025, has set Friday, August 01, 2025, as the record date for determining the eligibility of shareholders to receive the final dividend for the financial year ended March 31, 2025. The company had previously recommended a final dividend of ₹0.80 per equity share, which is equivalent to 80% of the face value of ₹1/- per share.
| Particulars | Details |
|---|---|
| Dividend per share (FY25) | ₹0.80 (80%) |
| Face Value per share | ₹1.00 |
| Record Date for Dividend | August 01, 2025 (Friday) |
| AGM Date | August 08, 2025 (Friday) |
| AGM Time | 9:00 a.m. (IST) |
| AGM Mode | Video Conferencing (VC)/Other Audio Visual Means (OAVM) |
| Dividend Payment Date (if approved) | On or after August 21, 2025 (Thursday) |
Detailed Analysis
The final dividend of ₹0.80 per equity share for the financial year ended March 31, 2025, was initially recommended by the Board of Directors at their meeting held on May 19, 2025. This recommendation is subject to the approval of the company's members at the upcoming 33rd Annual General Meeting (AGM). The setting of August 01, 2025, as the record date is a crucial step, as only shareholders holding shares on this specific date will be eligible to receive the dividend, provided it is approved at the AGM.
The 33rd Annual General Meeting of Marksans Pharma Ltd. is scheduled to be held on Friday, August 08, 2025, at 9:00 a.m. (IST). In line with current practices, the meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM), facilitating broader participation while adhering to safety protocols. The Notice of the AGM, along with the Annual Report for FY 2025, will be dispatched to eligible members via electronic mode. This includes members whose email addresses are registered with the company, its Registrar and Transfer Agent, or the Depositories. Furthermore, these documents will also be made available on the company's official website and the websites of the stock exchanges in due course, ensuring transparency and accessibility for all stakeholders.
Should the final dividend be approved by the shareholders at the AGM, the payment will be processed on or after Thursday, August 21, 2025. The payment will be subject to the deduction of applicable tax at source, as per prevailing tax regulations. This timeline provides clarity to investors regarding the expected receipt of their dividend payouts, contingent upon the necessary shareholder approval.
Additional Context
The Board of Directors meeting, which commenced at 11:20 a.m. and concluded at 11:50 a.m. on July 11, 2025, was convened to discuss and approve several key corporate matters, including the finalization of the AGM details and the record date for the dividend. This announcement is made in compliance with Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable regulations. Such disclosures are vital for maintaining transparency and keeping the stock exchanges and the investing public informed about significant corporate actions.
Market Impact
The declaration of a record date for the final dividend, along with the scheduled AGM, provides important information for Marksans Pharma's shareholders. The dividend, if approved, represents a return on investment for shareholders and reflects the company's financial performance for the fiscal year 2025. Investors who wish to be eligible for this dividend must ensure their shares are in their demat accounts by the record date of August 01, 2025. The AGM serves as a crucial platform for shareholders to exercise their voting rights, including the approval of the dividend, and to engage with the company's management on its performance and future strategies.
